Key Takeaways
- Soft quarter, margin upgrade: Domestic organic growth decelerated to low double digits in a soft Q4, but management lifted its EBITDA margin guidance to 25%-27% for the next couple of years, citing easing input costs and a better Azmarda sourcing mix.
- Azmarda holds its ground post-LOE: The brand maintained pre-exclusivity volumes and an 18% value share despite generic entry, and management expects the competitive picture to look "very different in 6 months."
- Lozenges are the next growth vector: The CMO business is riding strong lozenge demand, with new launches planned in sleep, anti-inflammatory and immunity categories, plus a South Africa home-market launch in Q2.
- Chronic portfolio is the steady engine: Chronic therapies grew mid-teens plus, pushing the chronic share to ~53% with a medium-term target of 60%, while the acquired portfolio (Sporlac, Razel) is scaling as planned.
- What to watch next quarter: Whether the April momentum (18% growth, fastest in top 25) sustains, the pace of gross margin recovery toward 65%, and any detail on the Ranitidine litigation once management receives it.
Domestic Business & Portfolio Strategy
- Q4 softness was category-driven: IPM saw an upsurge in respiratory, conjunctivitis and upper respiratory tract infections, categories where JB does not have a portfolio. The chronic portfolio grew mid-teens plus while the acute portfolio grew high single digit.
- Organic growth deceleration: The organic portfolio in steady state grows at mid-teens; March tends to be soft, causing the Q4 low double-digit figure. No base effect or NLEM impact was cited.
- April rebound: The market grew ~11% while JB grew ~18% with 11% volume growth, making it the fastest-growing company in the top 25. Price benefit from April increases should start showing from June or part of May, given 41-60 days of inventory.
- Prescription scale: JB is now the 15th ranked company in India by prescriptions, generating close to 5 crore prescriptions per quarter, and the fastest-growing among the top 25 in IPM for two consecutive years.
- Big-brand depth over width: The strategy rests on making big brands bigger through lifecycle management, incremental innovation, patient consumerization and better adherence in chronic therapy, rather than spreading across many categories.
- Acquired portfolio scaling: Sporlac market share moved from 7.5% to ~9-10% and revenue from ~INR60 crore to INR90 crore via better penetration, distribution and new versions. Razel (rosuvastatin) integration is smooth and JB is the 10th ranked company in that molecule.
- MR productivity drivers: A mix of disciplined field discussions, iPad investment, sales force automation, digital retailing, big brands gaining ranks, other INR10-15 crore brands growing well, and the acquired portfolio helping in mass categories. Rantac and Metrogyl are the top two prescribed brands.
Chopra: "We are not into 15 categories of portfolio. We are into half a dozen. So, that helps us with now 3, 4 teams, one team focusing on chronic business, one team focusing on acute business, one team focusing on hospital and your overall business in respiratory and paediatrics."
Azmarda: Post-LOE Dynamics
- Volume resilience: Pre-exclusivity volumes are up 20% in April versus the pre/post-LOE period, and the brand continues to draw monthly volume similar to pre-exclusivity periods.
- Market share held: Some volume market share was lost to generics, but overall value share was maintained at 18%. The brand remains EBITDA accretive even after LOE erosion.
- Sourcing tailwind: With the Azmarda sourcing mix improving, gross margins will significantly improve, contributing to the margin guidance upgrade. Management declined to divulge sourcing strategy details.
- Competitive outlook: Competition is stiff now, but management expects the story to look "very different in 6 months" with selective players remaining, and is staying patient with its planned approach.
Chopra: "Azmarda, right now, the competition is stiff. But I think the story would be very different in 6 months, where you will see selective players and being patient and looking at in terms of continuing to do what we have planned."
CMO & Lozenges Business
- Lozenges driving the upsurge: Increasing acceptance and continued demand for lozenges was the key driver, with a number of products introduced with marquee partners. Southeast Asia performed best in the last financial year; other regions include MENA, Australia, New Zealand and Canada.
- New category launches: Lozenges are being developed in sleep disorders, anti-inflammatory categories and immunity, with launches planned in Q4 of FY24.
- South Africa home-market launch: Lozenges will launch in South Africa, JB's home market, probably in Q2.
- India testing: Three to four lozenges have been introduced in India using a different model involving digital selling and retail activities.
- North America on hold: Management has a long-term view on North America but says it is too early to comment on strategy, and emphasized the focus is on medicated lozenges, not conventional ones.
- CMO outlook: Low double-digit to mid-teens growth expected, with a handsome order book for the first three to four months. Performance could outscore depending on the post-viral cough and cold season, with more clarity by August or September.
Khanna: "As far as North America is concerned, yes, a long-term view on that, but too early to comment on what exactly will be our strategy there. Also please note, we have always maintained like Nikhil mentioned earlier, we operate in the medicated lozenges space, right? We don't want to do conventional lozenges."
International Markets
- Russia normalization: Demand trends have normalized and are expected to continue going forward.
- South Africa profitability focus: Strategy centers on increasing private market share to drive profitability over the next couple of years.
- BGx markets performing: Sub-Sahara Africa, Latin America, Southeast Asia and the Middle East reported good results on the back of post-COVID demand normalcy. ROW international market YTD growth was around 12%.
- Geography disclosure declined: Management declined to divulge geography-wise or portfolio-wise share of branded generics within the INR1,000 crore international formulations revenue.
Margins, Costs & Balance Sheet
- EBITDA margin guidance upgraded: Revised from 24%-26% to 25%-27% for the next couple of years, backed by gains in Azmarda sourcing, better product mix, and RM/PM and freight softening.
- Gross margin recovery: First six to eight months of FY23 had inflationary pressure; from end of Q3 and Q4, pressure eased. With the Azmarda sourcing mix improving, gross margin should get closer to 65% in FY24 if conditions hold.
- Other expenses uptick: A sequential increase of ~INR7-8 crore included integration-related costs from the Razel acquisition and some expense seasonality moving into Q4. Management advises looking at the full year rather than extrapolating the quarter.
- Brand amortization: INR14 crore in amortization cost related to brands will continue at a similar pace next year.
- Debt repayment timeline: JB will turn cash positive or zero debt by Q3 this year. If no significant investment opportunity appears in one to two quarters, loan repayment can begin.
- ROCE trajectory: Expected to reach 25%-26% by end of next fiscal, with a target of 30%+ in approximately three years.
- Capital deployment: If no M&A opportunities arise, the priority is debt repayment. Once debt is repaid, the question will be addressed next year. No significant greenfield expansion is planned; capex will stay steady at ~INR70 crore.
- PAT growth conversion: EBITDA growth should start transforming into PAT numbers in FY23-24, driven by strong cash flow generation and turning net cash positive.
Chopra: "Going ahead for next couple of years, we are revising our EBITDA margin guidance from 24% to 26% to 25% to 27%. That is what we would like to share."
M&A & Portfolio Shaping
- Deal criteria: JB will continue to evaluate opportunities, preferring deals in therapies where it is already present for greater synergy. Historically, pricing has been 3x-4x of top line and around 15x-18x of EBITDA.
- Chronic share ambition: Medium-term target is to achieve 60% chronic share, up from the current ~53%.
- CDMO optionality: More therapeutic options are available to share with partners, plus new launches in the BGx world.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin | 25%-27% (revised from 24%-26%) | Next couple of years |
| Gross margin | Closer to 65% | FY24, if conditions hold |
| Debt repayment | Turn cash positive / zero debt | By Q3 FY24 |
| ROCE | 25%-26%, then 30%+ | End of next fiscal; ~3 years |
| Chronic share | 60% | Medium term |
| CMO growth | Low double-digit to mid-teens | FY24 |
| South Africa lozenge launch | Home-market launch | Q2 FY24 |
| New lozenge categories | Sleep, anti-inflammatory, immunity | Q4 FY24 |
| Overall business growth | 12%-14% revenue; 16%-18% EBITDA | FY24 |
| Azmarda competitive landscape | "Story would be very different" with selective players | ~6 months |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹762 cr, +22% YoY |
| Full-year revenue | ₹3,149 cr, crossing ₹3,000 cr milestone |
| Domestic formulation revenue | ₹380 cr, +29% YoY; full year ₹1,640 cr, +38% |
| Gross margin | 63.9%, vs 65.9% in Q4 FY22; sequential improvement from 62.3% in Q3 |
| Operating EBITDA (before ESOP) | ₹181 cr, +21% YoY; margin flat vs Q4 FY22 |
| Operating EBITDA margin guidance | 25%–27%, revised from 24%–26% for next couple of years |
| Profit after tax | ₹88 cr, +4% YoY; full year ₹410 cr |
| Effective tax rate | 26% for FY23 |
| Operating cash flow | ₹626 cr for FY23, vs ₹170 cr in FY22 |
| Net debt | ₹266 cr, improved from ₹429 cr in Dec '22 |
| Net working capital days | 89 days, improved from 111 days in FY22 |
| CMO business revenue | ₹406 cr for FY23, +60% YoY; Q4 growth +18% |
| Domestic business growth vs IPM | 22% vs IPM growth of 8% (IQVIA MAT March 2023) |
| Chronic portfolio growth | 24% in FY23 vs 11% IPM chronic growth |
| MR productivity | ₹6.2 lakhs in FY23, up from ₹5.4 lakhs in FY22 |
| MR count | ~2,200 |
| Chronic revenue share | ~53% |
| Azmarda IQVIA rank | #261, gained 125 ranks (MAT March 2023) |
| Azmarda volume trend | Up ~20% in recent months vs pre-exclusivity period |
| Acquired portfolio quarterly revenue | ~₹80 cr |
| ROCE | ~21% in FY23; target 25%–26% by end of next fiscal, 30%+ in ~3 years |
| Revenue growth guidance | 12%–14% for next couple of years |
| EBITDA growth guidance | 16%–18% for next couple of years |